Advertisement
RVTY vs TMO
Which Stock Would AI Choose? Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Thermo Fisher Scientific (TMO) boasts a much larger market capitalization of approximately $195 billion compared to Revvity's (RVTY) $10.4 billion, reflecting greater scale and diversification.
- TMO has shown stronger recent momentum with year-to-date gains of 9.13% and one-year returns of 23.50%, outperforming RVTY's 3.71% YTD (year-to-date) and 1.61% over one year.
- TMO trades at a lower trailing price-to-earnings (P/E) ratio of 29.67 versus RVTY's elevated 45.16, suggesting relatively better valuation.
- Both companies operate in the life sciences sector, but RVTY faces heightened regulatory risks, particularly from China, contributing to mixed sentiment.
- TMO benefits from positive expectations ahead of its upcoming quarterly earnings, with projected EPS (earnings per share) of $5.21.
- Tickeron's AI analysis favors TMO for its trend consistency and stability in recent market activity.
Introduction
Revvity (RVTY) and Thermo Fisher Scientific (TMO) are key players in the life sciences and diagnostics sector, providing essential tools, reagents, and services for research, healthcare, and pharmaceuticals. This comparison is particularly relevant for investors and traders seeking exposure to healthcare innovation amid evolving market dynamics, including regulatory shifts and biotech demand. By examining recent performance, financial metrics, and market positioning, readers can assess relative strengths in a sector driven by technological advancements and global health needs. Both stocks offer insights into growth potential versus stability trade-offs.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY) delivers health sciences solutions, including detection technologies, reagents, and services for genomics, oncology, and diagnostics. The company targets pharmaceutical firms, labs, and public health entities. In recent market activity, RVTY has exhibited mixed performance, with short-term gains of around 9% over the past month contrasting weaker longer-term trends. Closing near $93, the stock trades within its 52-week range of $81 to $118, reflecting volatility. Sentiment has been influenced by valuation concerns, elevated P/E ratios, and regulatory pressures, notably from China. Analysts note potential undervaluation but maintain cautious outlooks, with price targets averaging $115.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a global leader in life sciences solutions, analytical instruments, specialty diagnostics, and biopharma services across four segments. It serves diverse markets including research, clinical labs, and pharmaceuticals. Recent weeks have seen TMO demonstrate resilience amid volatility, closing around $526 within a 52-week range of $385 to $644. Year-to-date gains stand at 9%, bolstered by anticipation for Q1 earnings expected on April 23, with revenue forecasts of $10.83 billion. Positive analyst sentiment stems from strong profitability metrics like 15% profit margins and ROE (return on equity) of 13%, though shares have navigated broader sector pressures.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from over 351 available, each scanning thousands of tickers for real-time opportunities in stocks, ETFs, and crypto. These bots employ diverse strategies—such as trend-following, multi-agent portfolios, and risk-managed corridors with take-profit (2-3%) and stop-loss (2-10%) levels—across timeframes from 5 minutes to 60 days. Standout stats include annualized returns ranging from +15% to +168%, win rates of 54% to 88%, and profit factors up to 3.60. Focused on high-growth sectors like semiconductors, aerospace, and energy, they adapt to current volatility. Traders can explore these for automated signals tailored to market conditions.
Head-to-Head Comparison
Both RVTY and TMO thrive in life sciences tools and services, but TMO's broader model spans analytical instruments and biopharma services, driving superior revenue ($44.6 billion TTM versus $2.9 billion) and scale advantages. Growth drivers for TMO include proteomics alliances and earnings momentum, while RVTY emphasizes niche diagnostics amid softer demand. Recent momentum favors TMO with stronger YTD and one-year returns; risk factors weigh heavier on RVTY due to regulatory exposure and higher debt-to-equity (47% vs. 77%, but TMO manages via cash reserves). Market sentiment tilts toward TMO's stability in a high-interest environment.
Tickeron AI Verdict
Tickeron's AI currently leans toward Thermo Fisher Scientific (TMO) based on superior trend consistency, higher ROE, lower relative valuation, and positive catalysts like impending earnings. While RVTY offers potential upside from undervaluation narratives, its volatility and external risks suggest higher uncertainty. This positioning indicates TMO may exhibit stronger probabilistic outperformance in the near term amid sector rotation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- RVTY’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- RVTY’s TA Score: 3 bullish, 6 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а +1.31% price change this week, while TMO (@Medical Specialties) price change was -0.73% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
RVTY is expected to report earnings on Aug 03, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| RVTY | TMO | RVTY / TMO | |
| Capitalization | 11.1B | 174B | 6% |
| EBITDA | 773M | 11.7B | 7% |
| Gain YTD | 3.151 | -18.922 | -17% |
| P/E Ratio | 47.91 | 25.80 | 186% |
| Revenue | 2.9B | 45.2B | 6% |
| Total Cash | 860M | 3.26B | 26% |
| Total Debt | 3.35B | 43.2B | 8% |
RVTY | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 93 | |
SMR RATING 1..100 | 89 | 62 | |
PRICE GROWTH RATING 1..100 | 49 | 54 | |
P/E GROWTH RATING 1..100 | 32 | 47 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as RVTY (15). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as RVTY (100). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as RVTY (89). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (49) in the Medical Specialties industry is in the same range as TMO (54). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
RVTY's P/E Growth Rating (32) in the Medical Specialties industry is in the same range as TMO (47). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
| RVTY | TMO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 77% | 3 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 57% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 74% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 65% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 61% |
| Advances ODDS (%) | 6 days ago 66% | 14 days ago 62% |
| Declines ODDS (%) | 13 days ago 67% | 3 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 52% | 3 days ago 63% |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | -1.83% | ||
| TMO - RVTY | 70% Closely correlated | -1.33% | ||
| IQV - RVTY | 66% Loosely correlated | +0.22% | ||
| A - RVTY | 65% Loosely correlated | +0.22% | ||
| CRL - RVTY | 65% Loosely correlated | -0.29% | ||
| DHR - RVTY | 64% Loosely correlated | -0.38% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.